Joss Reimer

Communicating with government officials about the proposed Safe Social Media Act (Bill C-34) as it relates to reducing the harms to children and their access to online content. Communicating with government officials about artificial intelligence (AI), including about (i) the potential regulation of AI by government, (ii) potential uses for AI in government, (iii) investments in AI by government, including via the AI Compute Access Fund, (iv) technological developments related to AI, (v) the promotion of AI literacy, training and skills development and (vi) the development, implementation and amendment of AI policies, including but not limited to the “Canadian Guardrails for Generative AI – Code of Practice”, the “Voluntary Code of Conduct on the Responsible Development and Management of Advanced Generative AI Systems” and the “Canadian AI Sovereign Compute Strategy. Communicating with government officials about the Online Harms Act (formerly Bill C-63), more specifically about the regulation of online content. Communicating with government officials about the Digital Charter Implementation Act, 2022 (formerly Bill C-27), more specifically the creation of the Consumer Privacy Protection Act, the Personal Information and Data Protection Tribunal Act, and the Artificial Intelligence and Data Act. Communicating with government officials about the proposed Supporting Authorized Access to Information Act (Bill C-22) as it relates to the timely production of data and information. Communicating with government officials about the proposed Protecting Victims Act (Bill C-16) as it relates to youth safety online. Communicating with government officials, in general, about opportunities and challenges facing the creator economy, including as it relates to skills training, content creation and economic conditions. Communicating with government officials about the design and implementation of the National Anti-Fraud Strategy (announced in November 2025). Communicating with government officials about Bill S-209 (“An Act to restrict young persons’ online access to pornographic material”), including as it relates to the enactment of the Protecting Young Persons from Exposure to Pornography Act. Communicating with government officials about Bill C-8 (“An Act respecting cyber security, amending the Telecommunications Act and making consequential amendments to other Acts”), including as it relates to the amendment of the Telecommunications Act, S.C. 1993, c. 38, and the enactment of Critical Cyber Systems Protection Act. Communicating with government officials about industry and government efforts to promote online safety including but not limited to (i) combatting misinformation and disinformation, (ii) ensuring child safety, (iii) reducing online scams and fraudulent activity, (iv) minimizing online spam and (v) removing harmful online content. Communicating with government officials about proposed and existing youth privacy and age assurance measures, including the potential establishment of a youth privacy code. These communications may touch on, but are not limited to, the consultation launched by the Office of the Privacy Commissioner of Canada. Communicating with government officials about existing and proposed credit counselling regulations under the Financial Consumer Agency of Canada Act, S.C. 2001, c. 9 and the Bank Act, S.C. 1991, c. 46. Communicating with government officials, in general, about digital sovereignty. Communicating with government officials about "An Act to restrict young persons’ online access to sexually explicit material" (formerly in Bill S-210). Communicating with government officials about "An Act to enact the Protection of Minors in the Digital Age Act and to amend the Criminal Code" (formerly Bill C-412), more specifically about the regulation of online content. Communicating with government officials about "An Act respecting the interoperability of health information technology and to prohibit data blocking by

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Federal policies that relate to possible models of pharmacare Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations National Strategy for Drugs for Rare Diseases World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry World Health Organization (WHO) issues concerning the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Income Tax Act as it relates to biopharmaceutical products Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade agreements as they relate to the biopharmaceutical industry Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

Working with federal partners to streamline Health Canada policies and processes related to clinical trials and drug authorization specific to children, including the passage of C-265, an Act to Amend the Food and Drugs Act. Supporting the introduction and passing of legislation that would increase protections for children and youth online, including the passage of C-34, the Safe Social Media Act. Encouraging the development and strengthening of legislation and regulations that limit children's access to nicotine. Engaging federal partners on the national and international role that SickKids plays in child health care, research and education.